Pull to refresh
Logo
Shanghai fires gene-editing researchers after child's death in trial

Shanghai fires gene-editing researchers after child's death in trial

Rule Changes

Investigators found the team withheld monkey toxicity results, and that the consent form never listed death as a risk

Overview

Updated 2 hours ago

Shanghai authorities fired the neuroscientist who designed a custom gene editor for a six-year-old girl with an ultra-rare brain disorder, after she died following the treatment. The dismissals, announced on 13 November 2026, came with five-year bans from publicly funded science for the researcher and the lead author of the paper describing the work.

Investigators found the team had monkey-study results showing organ damage about a month before the infusion and did not pass them to the hospital ethics board or the clinician running the study. The consent form did not list death as a risk. The case runs through a Chinese pathway called investigator-initiated trials, which hospitals can operate without review from the national drug regulator.

Why it matters

China's fast-track hospital trials let experimental therapies reach patients without national regulator review. This case shows what happens when that shortcut fails.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

1
Child deaths in the trial
The six-year-old girl died of complications seven days after the infusion.
7 days
Infusion to death
A fatal immune reaction shut down her kidneys a week after the spinal injection.
5 years
Ban from science projects
Qiu and Kan Yang cannot lead or join publicly funded research until 2031.
$800,000
Family funding for the therapy
The parents provided cash and gifts to support development of a personalized treatment.
1.06 million yuan
Cash and gifts received by personnel
Investigators say staff accepted the money from the family; it has been returned or handed over.
$130,000
Undisclosed payments to lead author
Kan Yang did not disclose these payments, plus liquor, when the Nature paper was published.

Voices

Curated perspectives — historical figures and your fellow readers.

Sign up to generate historical perspectives on this story.

People Involved

Organizations Involved

Timeline

July 2023 November 2026

8 events Latest: Today
Tap a bar to jump to that date
  1. Nature reports the dismissals

    Today Report

    Nature details the firings and notes that the clinician overseeing the study was also removed from his research post.

  2. China tightens oversight of hospital-run trials

    Regulation

    The government increases scrutiny of investigator-initiated trials, the pathway that bypassed national drug regulators.

  3. Nature publishes the therapy paper

    Publication

    The paper describes the customized base editor but omits the child's death and the monkey toxicity findings.

  4. Girl dies after spinal infusion

    Death

    She receives trillions of engineered viruses into her spine; a fatal immune reaction shuts down her kidneys seven days later.

  5. Hospital ethics board clears the trial

    Approval

    Xinhua Hospital's ethics committee approves the study, later judged to have reviewed safety evidence inadequately.

  6. Family asks Qiu for a custom therapy

    Origin

    The parents of a girl with Snijders Blok–Campeau syndrome contact Qiu and later provide about $800,000 in cash and gifts to fund a personalized treatment.

Scenarios

1

Nature retracts the gene-editing paper

Likely Resolves by Q1 2027

Discussed by: The child's parents and the outside scientists who reviewed the case for Science and Retraction Watch, as reported by Science

The paper already carries an expression of concern. A retraction would require the journal to conclude that the undisclosed death, the omitted monkey toxicity data, and the conflict-of-interest failure undermine the published findings. Nature's deputy editor has said an update is expected shortly, which puts a decision on a near-term timetable.

2

Prosecutors charge Qiu over the trial

Possible Resolves by End of 2027

Discussed by: Bioethicists Renzong Qiu and Li Du, who compare the case to He Jiankui's criminal prosecution

The Shanghai investigation produced administrative penalties, not criminal charges. A criminal referral would rest on whether the failure to disclose the monkey toxicity data and the acceptance of family money cross from research misconduct into an offense such as illegal medical practice. Renzong Qiu's comparison to the He Jiankui case is the main public argument for prosecution.

3

Beijing issues national rules for investigator-initiated trials

Likely Resolves by Q2 2027

Discussed by: Lawyer Jiayou Shi and bioethicist Li Du, both of whom expect tighter hospital review

The trial ran under investigator-initiated trials, which hospitals can operate without national drug regulator review. Shanghai has already drafted a special inspection plan for clinical research on new biomedical technology. The open question is whether that becomes a national rule or stays a local enforcement push.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

November 2018 – December 2019

He Jiankui gene-edited babies (2018)

He Jiankui, a biophysicist in Shenzhen, announced that twin girls had been born from embryos he edited to disable CCR5, a gene linked to HIV entry. Chinese authorities detained him, and a court sentenced him in December 2019 to three years in prison and a 3 million yuan fine.

Then

China tightened rules on human embryo research and stopped similar work.

Now

He became the reference case for reckless gene editing, and Chinese clinical gene editing moved under tighter review.

Why this matters now

Bioethicist Renzong Qiu called the Shanghai case 'a second He Jiankui,' and the comparison is the main argument for criminal accountability.

September 1999

Jesse Gelsinger gene therapy death (1999)

Jesse Gelsinger, 18, died four days after receiving an experimental gene therapy vector at the University of Pennsylvania. He had a mild form of a liver enzyme disorder. The consent form did not disclose that earlier patients had suffered serious liver damage, and his ammonia levels were too high for the trial's own entry criteria.

Then

The Food and Drug Administration halted the trial and found informed-consent and safety violations; the university and researchers faced sanctions.

Now

The case became the standard example of consent failure in gene therapy and led to stronger federal oversight of human gene-transfer trials.

Why this matters now

The Shanghai consent form omitted death as a risk, the same kind of disclosure failure that defined Gelsinger's case.

1999 – 2004

French X-SCID gene therapy trials (late 1990s – early 2000s)

French researchers treated infants with X-linked severe combined immunodeficiency using retroviral gene therapy. In the early 2000s, several treated children developed leukemia-like illness after the virus inserted near a cancer-linked gene. Trials were halted, and one patient later died.

Then

Trials paused and regulators added long-term follow-up requirements for integrating vectors.

Now

The field shifted toward safer vector designs and longer monitoring of treated patients.

Why this matters now

It shows how one serious adverse event can pause an entire class of therapy and force redesign, which is the pressure now building on China's gene-editing pipeline.

Sources

(10)